Pilatus Biosciences, a clinical-stage biopharmaceutical company developing novel metabolic checkpoint immunotherapies to address unmet medical needs in cancer and immune-related diseases, announced that new preclinical data from PLT012, its lead first-in-class CD36-targeting monoclonal antibody, will be presented at the European Respiratory Society (ERS) International Congress 2026, held September 5-9, 2026, in Barcelona, Spain.
The findings expand the potential applications of Pilatus’s CD36 metabolic checkpoint platform beyond oncology and MASH, demonstrating disease-modifying activity in preclinical models of chronic obstructive pulmonary disease (COPD). The presentation will highlight PLT012’s ability to selectively inhibit CD36, a central regulator of lipid metabolism, chronic inflammation and tissue repair. In preclinical models of COPD, PLT012 demonstrated the ability to reduce inflammation, preserve alveolar architecture and improve lung function, supporting its potential as a disease-modifying therapy.
